This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): gatifloxacin ophthalmic solution 0.3%, Gatiflo 0.3% (Japan), Zymar X/Zymaxid (0.5%)
Description: Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent atC7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
Deal Structure: Kyorin originated the compound and in August 1997, entered into a licensing agreement with Senju for Japan territory. Under the Agreement, Kyorin supplies gatifloxacin bulk material to Senju, who in turn manufactures and markets the product. Royalties due to Kyorin from Senju will be based on a certain percentage of Senju's sales of the product.
Allergan licensed Zymar from Kyorin Pharmaceutical and has worldwide ophthalmic commercial rights excluding Japan, Korea, Taiwan and certain other countries in Asia.
Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.
In March 2015, Actavis announced that...See full deal structure in Biomedtracker
Partners: Kyorin Pharmaceutical Co., Ltd. Senju Pharmaceutical Co., Ltd.
Pink Sheet Allergan Zymar approval
Additional information available to subscribers only: